60 Degrees Pharmaceuticals is launching B-FREE, a Phase 2 open-label trial evaluating the ARAKODA (tafenoquine) regimen as a potential treatment for chronic babesiosis. The study, registered as NCT06656351, is slated to begin in early November and run for roughly 12 months. It will test a 90-day, weekly oral dosing schedule following a short loading phase, with the primary endpoint focused on resolution of severe fatigue at Day 90 via a validated patient-reported outcome measure, alongside assessments of parasite eradication. Up to 100 patients will be enrolled to complete at least 16 cases confirmed via the high-sensitivity RNA amplification assay used by the American Red Cross to screen blood donations. Additional CLIA-validated RT-PCR assays will be used serially to track detectability and clearance in real-world testing environments.
The strategic bet is clear: define and validate a poorly characterized, high-need clinical entity with an existing molecule, and move quickly where no approved therapy or consensus treatment guideline exists. The choice of an open-label design with a PRO primary endpoint in an infectious disease setting is unconventional, but it aligns with the symptom burden that drives care seeking in this population. The core question is whether such a signal-generating study can credibly anchor a registrational path, or at a minimum catalyze a larger, controlled program that satisfies regulators, payers, and guideline bodies. The company’s engagement of patient communities in branding the study underscores a patient-centric posture, but the commercial prize will hinge on evidentiary rigor rather than advocacy momentum.
This matters now because babesiosis incidence is rising, particularly in the Northeast, with older and immunocompromised individuals at elevated risk. Clinicians lack clear guidance for chronic or persistent presentations, and payers face growing off-label utilization without standardized diagnostics or endpoints. The study’s reliance on a highly sensitive, non-commercial RNA assay for confirmation could sharpen scientific clarity while creating a translation gap for routine care and reimbursement. If B-FREE can quantify how often commercial RT-PCRs detect confirmed infections and whether those signals clear with therapy, it could inform both diagnostic policy and real-world coverage decisions.
The initiative fits broader industry patterns. Repurposing a military-discovered antimalarial with a long half-life and convenient weekly dosing is a practical route to speed development, control cost, and potentially qualify for orphan pathways in a niche but expanding vector-borne market. Non-dilutive public-sector support, combined with targeted trials that blend PROs and parasitologic readouts, reflects how smaller companies are navigating capital scarcity while addressing “long” post-infectious syndromes that challenge traditional endpoints. Growing climate-driven tick exposure and heightened public awareness around Lyme and coinfections are expanding the addressable market while intensifying scrutiny on diagnostic validity and treatment claims.
What to watch next: the rate of enrollment and the proportion of patients who can be objectively confirmed by the RNA screen; concordance between blood bank and commercial assays; the magnitude and durability of fatigue improvement; and the safety profile of tafenoquine in a chronic dosing context, given known considerations such as G6PD status. A positive signal would set the stage for a randomized, controlled Phase 3 that pairs hard parasitological endpoints with functional outcomes and may justify parallel development of a companion diagnostic strategy. The strategic question for leaders is whether this program can move the field from anecdote and off-label practice to a scalable, reimbursable standard—or whether the evidence bar for chronic babesiosis will ultimately require a heavier lift than repurposing alone can deliver.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
